<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775227</url>
  </required_header>
  <id_info>
    <org_study_id>HYKS-190116</org_study_id>
    <nct_id>NCT02775227</nct_id>
  </id_info>
  <brief_title>Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications</brief_title>
  <official_title>Hydrocortisone vs Pasireotide in Preventing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <brief_summary>
    <textblock>
      Pancreatic resections carry a high risk for complications, especially pancreatic fistula.
      Both hydrocortisone and pasireotide have been shown to be effective in reducing complications
      in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these
      two drugs in preventing complications of pancreatic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Comprehensive Complication Index</measure>
    <time_frame>30 days postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications (Clavien-Dindo classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pancreatic fistula (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative delayed gastric emptying (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-pancreatectomy hemorrhage (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay, days</measure>
    <time_frame>During hospital stay, on average 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients receiving adjuvant therapy</measure>
    <time_frame>6 months postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Pancreatic Fistula</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <arm_group_label>Pasireotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for pancreatic surgery (pancreaticoduodenectomy, distal
             pancreatectomy, enucleation, or other type of pancreatic resection)

        Exclusion Criteria:

          -  Preoperative exclusion criteria:

          -  Atrophic pancreas and/or dilated pancreatic duct at the site of planned pancreatic
             transsection (applies only to patients undergoing pancreaticoduodenectomy)

          -  Total pancreatectomy planned

          -  Allergy or other contraindication for hydrocortisone or pasireotide

          -  Age &lt; 18 years

          -  No informed consent

          -  Intraoperative exclusion criteria:

          -  Pancreatic resection cancelled (e.g. disseminated cancer)

          -  Hard pancreas and/or dilated pancreatic duct discovered during operation (applies only
             to patients undergoing pancreaticoduodenectomy)

          -  Total pancreatectomy is performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ville Sallinen, MD, PhD</last_name>
    <email>ville.sallinen@helsinki.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ville Sallinen, MD, PhD</last_name>
      <email>ville.sallinen@helsinki.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2016</study_first_submitted>
  <study_first_submitted_qc>May 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

